Characteristics of deslanoside-induced modulation on jejunal contractility

Table 1 Effects of deslanoside on the contractility of jejunal smooth muscle pretreated with receptor antagonist

Agents	Normal contractile state		Low contractile state		High contractile state
	Pre-deslanoside	Post-deslanoside	Pre-deslanoside	Post-deslanoside	Pre-deslanoside	Post-deslanoside
Krebs buffer	100.0 ± 12.1	149.0 ± 13.0b	39.1 ± 2.8	89.1 ± 5.1b	177.7 ± 16.0	109.3 ± 11.9b
Atropin	93.3 ± 6.3	155.0 ± 15.1b	29.1 ± 1.1	32.4 ± 3.3	149.7 ± 11.0	100.3 ± 11.2b
Diphenhydramine	109.0 ± 14.3	145.2 ± 13.1b	46.5 ± 3.8	94.0 ± 4.9b	169.6 ± 15. 2	108.5 ± 11.6b
Cimetidine	100.0 ± 11.8	153.4 ± 13.0b	42.9 ± 3.9	93.4 ± 8.1b	180.1 ± 17.4	113.3 ± 12.1b
Phentolamine	92.5 ± 6.5	160.6 ± 16.2b	55.4 ± 5.5	90.6 ± 5.2b	189.3 ± 19.2	184.5 ± 17.2
Propranolol	89.4 ± 9.8	145.5 ± 14.2b	33.2 ± 2.6	95.6 ± 7.8b	163.1 ± 16.1	161.7 ± 17.3
L-NNA	103.0 ± 11.3	150.0 ± 13.2b	51.3 ± 4.6	119.6 ± 12.5b	190.5 ± 18.2	195.1 ± 19.1

Contractile amplitude of isolated jejunal smooth muscle fragment in normal contractile state is defined as 100% (control). Other data are the relative value (%) compared with control, and are expressed as the mean ± SE;

^bP < 0.01 vs the data prior to deslanoside treatment (n = 6). L-NNA: L-NG-nitroarginine.